Hasmukh J Prajapati
Overview
Explore the profile of Hasmukh J Prajapati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crook J, Lu Z, Wang X, Henderson N, Proctor K, Maller V, et al.
J Pediatr Surg
. 2021 Aug;
57(9):229-233.
PMID: 34456040
Purpose: We sought to identify clinical features associated with difficult subcutaneous port removals in children. Methods: Ports placed between April 2014 and September 2017 at our institution were prospectively tracked...
2.
Morgan K, Prajapati H, Frett M
A A Pract
. 2021 Aug;
15(8):e01518.
PMID: 34428775
Liposomal bupivacaine is a long-acting amide local anesthetic with a limited list of indications. At the time of publication, use is limited to field block and surgical wound infiltration and,...
3.
VanHouwelingen L, Veras L, Lu M, Wynn L, Wu J, Prajapati H, et al.
J Pediatr Surg
. 2019 Jan;
54(1):145-149.
PMID: 30661598
Background: The risk of infection associated with subcutaneous port (SQP) placement in patients with neutropenia remains unclear. We reviewed the rate of early infectious complications (<30 days) following SQP placement...
4.
Prajapati H, Kim H
PLoS One
. 2017 Feb;
12(2):e0170750.
PMID: 28170405
Purpose: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE)....
5.
Prajapati H, Kavali P, Kim H
Pediatr Transplant
. 2016 Nov;
21(1).
PMID: 27796068
The aim of the study was to investigate the BiCx after the pediatric OLT and to assess the efficacy of the fluoroscopic-guided PBI in the patients with BiCx as compared...
6.
Ludwig J, Ambinder E, Ghodadra A, Xing M, Prajapati H, Kim H
Cardiovasc Intervent Radiol
. 2016 Mar;
39(7):1007-14.
PMID: 26964779
Objective: To investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate...
7.
Xing M, Kokabi N, Prajapati H, Close O, Ludwig J, Kim H
J Comp Eff Res
. 2016 Mar;
5(2):141-54.
PMID: 26946950
Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials...
8.
Xing M, Webber G, Prajapati H, Chen Z, El-Rayes B, Spivey J, et al.
J Gastroenterol Hepatol
. 2015 Feb;
30(7):1167-74.
PMID: 25675849
Background And Aim: The study aims to determine the effects of doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) therapies on health-related quality of life (HRQOL) in patients with unresectable hepatocellular carcinoma...
9.
Prajapati H, Xing M, Spivey J, Hanish S, El-Rayes B, Kauh J, et al.
AJR Am J Roentgenol
. 2014 Nov;
203(6):W706-14.
PMID: 25415737
Objective: The purpose of this study was to investigate the overall survival, efficacy, and safety of small (100-300 µm) versus large (300-500 and 500-700 µm) doxorubicin drug-eluting beads transarterial chemoembolization...
10.
Xing M, Prajapati H, Dhanasekaran R, Lawson D, Kokabi N, Eaton B, et al.
Am J Clin Oncol
. 2014 Aug;
40(1):27-34.
PMID: 25089529
Objectives: To investigate survival, efficacy, and safety of selective internal yttrium-90 radioembolization therapy (Y-SIRT) in patients with unresectable metastatic melanoma (MM) to liver refractory to systemic therapy. Methods: An IRB-approved...